M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Psychophysical Studies of Cancer Therapy Pain

Recruiting

Conditions: Advanced Cancer
Pain

Interventions: Other: Sensory Tests

First Posted Date: 2007-08-13

Last Posted Date: 2024-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 450

Registration Number: NCT00515060

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2007-08-10

Last Posted Date: 2020-09-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 121

Registration Number: NCT00514540

Locations: 🇺🇸
University of California-San Francisco, San Francisco, California, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines

Phase 1

Terminated

Conditions: Leukemia

Interventions: Biological: Autologous Dendritic Cells

First Posted Date: 2007-08-09

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00514189

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

Phase 1

Completed

Conditions: Neuroectodermal Tumor
Brain Metastases
Advanced Cancer

Interventions: Drug: Valproate
Drug: Etoposide

First Posted Date: 2007-08-08

Last Posted Date: 2012-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT00513162

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia

Completed

Conditions: Cervical Cancer

Interventions: Procedure: Colposcopy

First Posted Date: 2007-08-08

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00513123

Locations: 🇳🇬
University College Hospital, Ibadan, Oyo State, Nigeria
🇨🇦
British Columbia Cancer Research Center, Vancouver, British Columbia, Canada
🇺🇸
U.T. Health Science Center, Houston, Texas, United States

and more 2 locations

Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients

Phase 3

Completed

Conditions: Gastrointestinal Cancer
Lung Cancer

Interventions: Drug: Melatonin
Drug: Placebo

First Posted Date: 2007-08-08

Last Posted Date: 2012-12-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 82

Registration Number: NCT00513357

Locations: 🇺🇸
Joan Karnell Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Curbing Tobacco Use in Suburban and Rural Schools

Phase 1

Completed

Conditions: Tobacco Use Cessation

Interventions: Behavioral: Smoking Prevention Program
Behavioral: Focus Group
Behavioral: Survey

First Posted Date: 2007-08-08

Last Posted Date: 2017-11-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1289

Registration Number: NCT00513097

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

RTA 744 Injection in Patients With Leptomeningeal Disease

Phase 1

Terminated

Conditions: Neoplastic Meningitis
Solid Tumor
Lymphoma
Leukemia
Brain Tumor

Interventions: Drug: RTA 744

First Posted Date: 2007-08-07

Last Posted Date: 2016-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00512460

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

Not Applicable

Completed

Conditions: Advanced Cancer

Interventions: Drug: Olanzapine

First Posted Date: 2007-08-07

Last Posted Date: 2011-09-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00512291

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis

Phase 2

Completed

Conditions: Penile Cancer

Interventions: Drug: Ifosfamide
Drug: Paclitaxel (Taxol)
Drug: Cisplatin

First Posted Date: 2007-08-07

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00512096

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy